vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $151.7M, roughly 1.1× Nutex Health, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -41.1%). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
ESPR vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $151.7M |
| Net Profit | — | $11.8M |
| Gross Margin | — | 30.4% |
| Operating Margin | 50.6% | 20.4% |
| Net Margin | — | 7.8% |
| Revenue YoY | 143.7% | -41.1% |
| Net Profit YoY | — | -80.8% |
| EPS (diluted) | $0.32 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $151.7M | ||
| Q3 25 | $87.3M | $267.8M | ||
| Q2 25 | $82.4M | $244.0M | ||
| Q1 25 | $65.0M | $211.8M | ||
| Q4 24 | $69.1M | $257.6M | ||
| Q3 24 | $51.6M | $78.8M | ||
| Q2 24 | $73.8M | $76.1M | ||
| Q1 24 | $137.7M | $67.5M |
| Q4 25 | — | $11.8M | ||
| Q3 25 | $-31.3M | $55.4M | ||
| Q2 25 | $-12.7M | $-17.7M | ||
| Q1 25 | $-40.5M | $21.2M | ||
| Q4 24 | — | $61.6M | ||
| Q3 24 | $-29.5M | $-8.8M | ||
| Q2 24 | $-61.9M | $-364.0K | ||
| Q1 24 | $61.0M | $-364.0K |
| Q4 25 | — | 30.4% | ||
| Q3 25 | — | 57.8% | ||
| Q2 25 | — | 51.2% | ||
| Q1 25 | — | 55.9% | ||
| Q4 24 | — | 55.0% | ||
| Q3 24 | — | 27.8% | ||
| Q2 24 | — | 29.7% | ||
| Q1 24 | — | 15.1% |
| Q4 25 | 50.6% | 20.4% | ||
| Q3 25 | -11.4% | 48.7% | ||
| Q2 25 | 8.6% | 13.8% | ||
| Q1 25 | -34.0% | 38.1% | ||
| Q4 24 | -6.4% | 44.4% | ||
| Q3 24 | -31.0% | 12.3% | ||
| Q2 24 | 3.5% | 7.0% | ||
| Q1 24 | 52.5% | 2.1% |
| Q4 25 | — | 7.8% | ||
| Q3 25 | -35.9% | 20.7% | ||
| Q2 25 | -15.4% | -7.3% | ||
| Q1 25 | -62.2% | 10.0% | ||
| Q4 24 | — | 23.9% | ||
| Q3 24 | -57.2% | -11.2% | ||
| Q2 24 | -83.9% | -0.5% | ||
| Q1 24 | 44.3% | -0.5% |
| Q4 25 | $0.32 | $2.34 | ||
| Q3 25 | $-0.16 | $7.76 | ||
| Q2 25 | $-0.06 | $-2.95 | ||
| Q1 25 | $-0.21 | $3.33 | ||
| Q4 24 | $-0.14 | $11.56 | ||
| Q3 24 | $-0.15 | $-1.72 | ||
| Q2 24 | $-0.33 | $-0.07 | ||
| Q1 24 | $0.34 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $329.4M |
| Total Assets | $465.9M | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $185.6M | ||
| Q3 25 | $92.4M | $166.0M | ||
| Q2 25 | $86.1M | $96.7M | ||
| Q1 25 | $114.6M | $84.7M | ||
| Q4 24 | $144.8M | $40.6M | ||
| Q3 24 | $144.7M | $46.9M | ||
| Q2 24 | $189.3M | $40.8M | ||
| Q1 24 | $226.6M | $30.0M |
| Q4 25 | $-302.0M | $329.4M | ||
| Q3 25 | $-451.4M | $317.2M | ||
| Q2 25 | $-433.5M | $235.3M | ||
| Q1 25 | $-426.2M | $176.9M | ||
| Q4 24 | $-388.7M | $132.4M | ||
| Q3 24 | $-370.2M | $60.4M | ||
| Q2 24 | $-344.2M | $62.7M | ||
| Q1 24 | $-294.3M | $63.0M |
| Q4 25 | $465.9M | $918.5M | ||
| Q3 25 | $364.0M | $964.5M | ||
| Q2 25 | $347.1M | $841.0M | ||
| Q1 25 | $324.0M | $761.9M | ||
| Q4 24 | $343.8M | $655.3M | ||
| Q3 24 | $314.1M | $438.5M | ||
| Q2 24 | $352.3M | $422.4M | ||
| Q1 24 | $373.1M | $404.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $70.4M |
| Free Cash FlowOCF − Capex | — | $69.0M |
| FCF MarginFCF / Revenue | — | 45.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | — | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $70.4M | ||
| Q3 25 | $-4.3M | $99.5M | ||
| Q2 25 | $-31.4M | $27.3M | ||
| Q1 25 | $-22.6M | $51.0M | ||
| Q4 24 | $-35.0M | $54.0K | ||
| Q3 24 | $-35.3M | $6.8M | ||
| Q2 24 | $-7.2M | $13.3M | ||
| Q1 24 | $53.8M | $3.1M |
| Q4 25 | — | $69.0M | ||
| Q3 25 | — | $99.2M | ||
| Q2 25 | — | $26.5M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | — | $-341.0K | ||
| Q3 24 | $-35.5M | $6.2M | ||
| Q2 24 | $-7.3M | $12.7M | ||
| Q1 24 | $53.8M | $2.3M |
| Q4 25 | — | 45.5% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | 24.0% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | -68.7% | 7.8% | ||
| Q2 24 | -9.9% | 16.7% | ||
| Q1 24 | 39.0% | 3.4% |
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.3% | 0.8% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 1.1% |
| Q4 25 | — | 5.95× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.40× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
